RPRX logo

Royalty Pharma plc (RPRX)

$68.68

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RPRX

Market cap

$39.40B

EPS

1.52

P/E ratio

30.4

Price to sales

12.91

Dividend yield

1.369%

Beta

0.370273

Price on RPRX

Previous close

$68.53

Today's open

$67.92

Day's range

$67.62 - $68.77

52 week range

$37.31 - $70.37

Profile about RPRX

CEO

Pablo Legorreta

Employees

100

Headquarters

New York, NY

Exchange

Nasdaq Global Select

Shares outstanding

573605303

Issue type

Common Stock

RPRX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on RPRX

Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript

Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • a day ago

news preview

Royalty Pharma to present at the UBS Global Biopharma Conference

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 5:40 a.m. ET / 10:40 a.m. GMT.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Royalty Pharma: Stronger Royalty Growth Supports Further Upside

Royalty Pharma's Q3 royalty receipts increased 9% to $883 million, led by strong growth in Tremfya, Voranigo, and Evrysdi. Vertex now accounts for approximately 25% of royalty receipts, indicating that newer medicines are gradually reducing the portfolio's concentration. Management raised its 2026 guidance again, while new drug approvals, additional investments, and share buybacks support future growth.

news source

Seeking Alpha • Nov 12, 2026

news preview

3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them

Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.

news source

24/7 Wall Street • Nov 10, 2026

news preview

Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug

Revolution Medicines' daraxonrasib has received FDA approval. Royalty Pharma estimates that the drug could produce peak revenues of $11 billion.

news source

The Motley Fool • Nov 8, 2026

news preview

Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?

Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

news source

Zacks Investment Research • Nov 6, 2026

news preview

Royalty Pharma Q3 Earnings Call Highlights

Royalty Pharma NASDAQ: RPRX reported third-quarter portfolio receipts of $890 million, up 9% from a year earlier, as growth in its diversified royalty portfolio offset declines in certain products. The company raised its full-year 2026 outlook for the third consecutive quarter, citing continued momentum in recurring royalty receipts.

news source

MarketBeat • Nov 4, 2026

news preview

Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript

Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Royalty Pharma reports third quarter 2026 results

Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.17 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Royalty Pharma plc

Open an M1 investment account to buy and sell Royalty Pharma plc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RPRX on M1